Navigation Links
Neurochem reports results for third quarter of fiscal 2007
Date:11/7/2007

statistically significant difference in favor of the product candidate with respect to the primary endpoints over 18 months of treatment. However, a substantial difference observed in hippocampal volume did approach statistical significance. Due to significant interference from high between-site variations that complicated the statistical analyses beyond expectations, it was not possible to draw definitive conclusions with respect to the treatment effect of tramiprosate (ALZHEMED(TM)). Neurochem has established a Special Advisory Board comprised of regulatory, medical and statistical experts from the fields of AD, therapeutics for the central nervous system, functional assessments, imaging, biomarkers, and clinical trial design. The mandate of the Special Advisory Board is to assist Neurochem in reviewing and analyzing the data from the North American Phase III clinical trial and to provide advice to Neurochem on the tramiprosate (ALZHEMED(TM)) program. The North American Phase III clinical trial included 1,052 patients at 67 clinical centers across the US and Canada. All patients who completed the North American Phase III clinical trial were eligible to receive tramiprosate (ALZHEMED(TM)) in an open-label extension of the Phase III study. Neurochem is also currently conducting a European Phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of AD, with 973 mild-to-moderate AD patients enrolled at 69 clinical centers in 10 European countries. In August 2007, Neurochem stopped patient screening activities as it had met its recruitment target. For the nine-month period ended September 30, 2007, research and development expenses also included costs incurred to support the North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)), the ongoing open-label extension of the eprodisate (KIACTA(TM)) Phase II/III study, as well as ongoing drug discovery programs.

Research tax credits and grants amounted to $434,000 this quarter ($1,434,
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... Routines… every family ... routines can help make things easier for parents, caregivers and children too. Here are ... transitions both big and small become more fluid. When a routine is implemented into ...
(Date:9/1/2015)... ... September 01, 2015 , ... Specialty Technical ... updated International Audit Protocol Consortium (IAPC) EHS audit protocol for the European Union. ... scope of their EHS regulatory obligations and rapidly collect, share, archive, and export ...
(Date:8/31/2015)... , ... September 01, 2015 , ... The PT Outcomes ... clinically relevant measures for physical therapy patients. The Registry is being developed by the ... Inc. stated "We are happy to be selected to contribute FOTO Outcomes measures as ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... in giving potential patients the resources they need to have a successful cosmetic ... board certified plastic surgeons; Cosmetic Town Journal is always ready to help. , ...
(Date:8/31/2015)... ... ... comes to undergoing a hair transplant, most patients have donor hair moved from one part ... hair on top of the scalp, as well as filling in areas missing hair, is ... other areas of their head. , What about patients who have a limited, or even ...
Breaking Medicine News(10 mins):Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2
... 2011 -- The portion of the brain responsible for visual ... study by researchers from the Hebrew University of Jerusalem and ... they read words in Braille show activity in precisely the ... readers read. The findings challenge the textbook notion that the ...
... & Infants Hospital of Rhode Island has been named ... Clinical Sciences Institute of OptumHealth, an independent audit company. ... are created equal. For complex medical conditions, the ... process, OptumHealth developed Centers of Excellence networks that provide ...
... D.C., 22 February 2011 Adolescence can herald the ... long-term consequences including developmental and social impairment. Research that ... can shine a bright light on the persistent disparities ... the fact that equitable mental health care across all ...
... MONDAY, Feb. 21 (HealthDay News) -- The experience of ... lives of women than men, a new study suggests. ... additional care, including follow-up and possibly counseling to optimally cope ... of the department of dermatology at Erasmus MC in ...
... BROOK, Ill. Radiologists who interpret a high volume of ... determining which suspicious lesions are not malignant, according to a ... of Radiology . "Contrary to our expectations, we ... study,s lead author, Diana S.M. Buist, Ph.D., M.P.H., senior investigator ...
... to experience more health-related quality of life issues than men ... skin cancer melanoma, according to a report in the February ... JAMA/Archives journals. "Although the prognosis is relatively good for ... risk for disease progression and have an increased risk of ...
Cached Medicine News:Health News:Brain doesn't need vision at all in order to 'read' material 2Health News:Brain doesn't need vision at all in order to 'read' material 3Health News:Women & Infants named Center of Excellence for Neonatal Care for fifth year 2Health News:Racial and ethnic minority adolescents less likely to receive treatment for major depression 2Health News:Surviving Melanoma May Take Different Toll on Women, Men 2Health News:Surviving Melanoma May Take Different Toll on Women, Men 3Health News:Higher volume reduces false positives in screening mammography 2Health News:Influence of skin cancer on quality of life appears more substantial for women 2
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3